Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00450775

Enrollment

Registered

2007-03-22

Start date

2007-03-31

Completion date

2008-03-31

Last updated

2008-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Scars

Brief summary

The purpose of this study is to evaluate the efficacy and patient acceptance of Dermatix Q for the prevention and treatment of scarring.

Interventions

DRUGDermatix Q

Dermatix Q applied twice daily

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Female or male patients at least 18 years of age * Patients who are at serious risk of hypertrophic scarring (due to family history, race, recent surgery, etc) * Able and willing to provide informed consent and likely to complete all study visits * All Fitzpatrick skin types will be evaluated

Exclusion criteria

* Known contraindications to Dermatix or any of its components * Age of scar is \> 4 months * Keloid scars (scars with increased fibroblastic activity that has exceeded the boundaries of the original scar)

Design outcomes

Primary

Measure	Time frame
efficacy	1 yr

Secondary

Measure	Time frame
patient acceptance	1 yr

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026